Grünenthal Group: First participants enrolled in Clinical Trial with Nociceptin/Orphanin peptide receptor (NOP) agonist
Aachen, Germany, 29 September 2021 – Today, Grünenthal announced that the first participants have been enrolled in a randomised, placebo- and active-controlled clinical trial for its peripherally restricted Nociceptin/Orphanin FQ peptide receptor (NOP) agonist. The compound is being developed to provide a non-opioid therapy option that offers a strong analgesic effect without the side effects commonly associated with opioids. The Experimental Medicine Trial will evaluate the extent and duration of the pharmacological effect of the oral NOP agonist in an experimental pain model. The results of the trial are expected to be available in early 2022.
The trial explores how the NOP agonist influences pain signalling and perception using laser evoked potentials (LEPs) in an experimental pain model with 30 healthy participants. On five different occasions, the participants will receive either the NOP agonist or pregabalin or placebo. The trial explores three different doses of the NOP agonist; pregabalin and placebo will be given to ensure control conditions. In the experimental pain model, a laser will generate a short tolerable painful heat stimulus on the participant’s skin which has been sensitised to mimic a temporary state of neuropathic pain. Both objective and subjective endpoints will be assessed in response to the laser stimuli, including electroencephalography (EEG) to measure brain activity and the Visual Analogue Scale (VAS) for subjective pain perception.
”This peripherally restricted, potent and selective NOP receptor agonist has shown analgesic effects in a wide range of pre-clinical pain models,” says Jan Adams, M.D., Chief Scientific Officer Grünenthal. “Millions of patients suffer from chronic neuropathic pain and are in need of better treatment options. With its unique mechanism of action, our NOP agonist may have the potential to provide these patients with a therapeutic benefit and an improved safety profile compared to the available standards of care.”
A First-in-Human clinical trial to assess the safety and tolerability profile and the pharmacokinetic characteristics of the NOP agonist is ongoing since December 2020. In addition, Grünenthal intends to start a Phase IIa trial to evaluate the compound’s efficacy in patients with painful diabetic peripheral neuropathy in 2022.
Grünenthal’s R&D pipeline includes multiple programmes across different targets, modalities and mechanisms of action to deliver better treatments for patients with severe pain conditions. In addition to developing its NOP agonist, Grünenthal is conducting a Phase I clinical trial with a Glucocorticoid Receptor Modulator (GRM) aiming to provide patients with a therapy option for chronic inflammatory diseases. Grünenthal recently announced the start of recruitment for a Phase III clinical trial with Qutenza® (capsaicin) 8% topical system in post-surgical neuropathic pain. In addition, Grünenthal intends to enrol the first patients with painful osteoarthritis of the knee in a Phase III clinical trial to investigate the efficacy, safety and tolerability of Resiniferatoxin by Q1 2022.
 Grünenthal Data on file
Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on working towards our vision of a world free of pain.
Grünenthal is headquartered in Aachen, Germany, and has affiliates in 29 countries across Europe, Latin America and the US. Our products are available in more than 100 countries. In 2020, Grünenthal employed around 4,500 people and achieved sales of € 1.3 bn.
More information: www.grunenthal.com
Follow us on:
LinkedIn: Grunenthal Group
For further information, please contact:
Christopher Jansen, Communication Business Partner
Phone: +49 241 569-1428
Florian Dieckmann, Head Global Communications
Phone: +49 241 569-2555
About news aktuell GmbH
As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Erste Foundation: Public benefit foundations: European conference opens in Vienna19.10.2021 16:25:18 CEST | Pressemelding
For three days (18-20 Oct.) 400 guests will discuss issues relating to the general topic “From crisis to opportunity – How can philanthropy accelerate sustainable change?”
Procolombia: Join the President of Colombia, Iván Duque, at this year’s Colombia Investment Summit19.10.2021 14:06:06 CEST | Press release
The seventh annual Colombia Investment Summit (CIS) will take place from Oct. 20-26 both remotely and in person in Bogotá. Organised by ProColombia, the organisation in charge of promoting foreign direct investment in Colombia, the event is expected to bring together more than 1,000 participants and over 300 international companies for three days of academic presentations and business matchmaking with local companies, project owners and government entities.
Börsenverein des Deutschen Buchhandels: Antje Rávik Strubel receives the German Book Prize 2021 for her novel “Blaue Frau” (“Blue Woman”)18.10.2021 18:55:00 CEST | Press release
The winner of the German Book Prize 2021 is Antje Rávik Strubel for her novel “Blaue Frau” (S. Fischer).
Fleetpool GmbH: Perfect Match: ALD acquires Fleetpool Group:13.10.2021 14:06:52 CEST | Press release
Fleetpool, the German pioneer and market leader in car subscriptions, and leading international mobility provider ALD are joining forces. The two companies have agreed the 100-percent acquisition of the Fleetpool Group by ALD, including its fleet of more than 10,000 vehicles.
Deutsche Hospitality: Deutsche Hospitality and the Porsche Design Group launch a unique hotel concept and plan at least 15 hotels in metropolises right across the world12.10.2021 13:00:00 CEST | Press release
Zeitgeist, Design and Service Excellence.
Deutsche Bundesstiftung Umwelt (DBU): “The award recipients give us hope”11.10.2021 09:41:00 CEST | Pressemelding
Ecologist and peatland researcher receive German Environmental Prize
Deutsche Bundesstiftung Umwelt (DBU): Steinmeier: Let us change course for climate protection and biodiversity11.10.2021 09:33:25 CEST | Pressemelding
Federal President presents German Environmental Prize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom